A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients
- Conditions
- Urinary IncontinenceOveractive Bladder
- Interventions
- Biological: Botulinum Toxin Type A
- First Posted Date
- 2015-11-10
- Last Posted Date
- 2016-07-21
- Lead Sponsor
- Allergan
- Target Recruit Count
- 168
- Registration Number
- NCT02601287
- Locations
- 🇰🇷
Pusan National University Hospital, Busan, Korea, Korea, Republic of
🇰🇷The Catholic University of Korea Bucheion St. Mary Hospital, Gyeonggi-do, Korea, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Korea, Republic of
A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia
- Conditions
- Presbyopia
- Interventions
- Drug: AGN-199201 ophthalmic solutionDrug: AGN-190584 ophthalmic solutionDrug: AGN-190584 vehicleDrug: AGN-199201 + AGN-190584 CombinationDrug: AGN-199201 vehicle
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Allergan
- Target Recruit Count
- 163
- Registration Number
- NCT02595528
- Locations
- 🇺🇸
Sall Research Medical Center, Artesia, California, United States
🇺🇸Milton M. Hom, OD, FAAO, Azusa, California, United States
🇺🇸WCCT Global, LLC, Costa Mesa, California, United States
A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in India
- Conditions
- Urinary IncontinenceOveractive Bladder
- Interventions
- Biological: botulinum toxin Type A
- First Posted Date
- 2015-10-29
- Last Posted Date
- 2018-03-26
- Lead Sponsor
- Allergan
- Target Recruit Count
- 250
- Registration Number
- NCT02590250
- Locations
- 🇮🇳
Dr. Ram Manohar Lohia Hospital, New Delhi, Delhi, India
🇮🇳Bodyline Hospitals, Ahmedabad, Gujarat, India
🇮🇳Fortis Hospitals, Bengaluru, Karnataka, India
A Multicenter Prospective Non-Interventional Study Assessing the Management of Canadian Women With Uterine Fibroids
- Conditions
- Leiomyoma
- Interventions
- Other: No Intervention
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Allergan
- Target Recruit Count
- 1500
- Registration Number
- NCT02580578
- Locations
- 🇨🇦
Children's and Women's Health Centre of British Columbia - The University of British Columbia, Vancouver, British Columbia, Canada
🇨🇦Minimally Invasive Gynecology Clinic, London, Ontario, Canada
🇨🇦Peter Lougheed Centre/University of Calgary, Calgary, Alberta, Canada
Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension
- Conditions
- Glaucoma, Open-AngleOcular Hypertension
- Interventions
- First Posted Date
- 2015-10-08
- Last Posted Date
- 2018-07-05
- Lead Sponsor
- Allergan
- Target Recruit Count
- 750
- Registration Number
- NCT02571712
- Locations
- 🇨🇳
Xuanwu Hospital Capital Medical University, Beijing, Beijing, China
🇨🇳Tongji Hospital of Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, China
🇨🇳Eye & ENT Hospital of Fudan University, Shanghai, Shanghai, China
A Study of Hyaluronic Acid Injectable Gel (VYC-25L) for Restoration and Creation of Facial Volume in the Chin and Jaw
- Conditions
- Chin Retrusion
- Interventions
- Device: Hyaluronic Acid Injectable Gel
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2017-12-13
- Lead Sponsor
- Allergan
- Target Recruit Count
- 120
- Registration Number
- NCT02559908
- Locations
- 🇳🇱
Joost Kroon Cosmetische Kliniek, Amsterdam, Netherlands
🇩🇪Dermatogische Privatpraxis CentroDerm GmbH, Wuppertal, Germany
🇩🇪Rosenpark Research Geschäftsbereich der Rosenparkklinik GmbH, Darmstadt, Germany
Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2016-09-02
- Lead Sponsor
- Allergan
- Target Recruit Count
- 315
- Registration Number
- NCT02557971
- Locations
- 🇺🇸
The Charlotte-Mecklenburg Hospital Authority DBA Carolinas Healthcare System, Charlotte, North Carolina, United States
🇺🇸University of California, Davis, Davis, California, United States
🇺🇸Capital Region Urology, Irvine, California, United States
A Safety and Efficacy Study of JUVÉDERM® VOLIFT® With Lidocaine and Restylane® for Nasolabial Folds in Chinese Adults
- Conditions
- Nasolabial Fold
- Interventions
- Device: Restylane®Device: JUVÉDERM® VOLIFT® with Lidocaine
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2017-08-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 175
- Registration Number
- NCT02558283
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
🇨🇳General Hospital of Guangzhou Military Command of PLA, Guangzhou, China
🇨🇳Union Hospital Tongji Medical College Huazhong University of Science and Technology, Guangzhou, China
Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Allergan
- Target Recruit Count
- 3423
- Registration Number
- NCT02555761
- Locations
- 🇰🇷
Ian Eye Center, Seoul, Korea, Republic of
🇰🇷Soonchunhyang University Cheonan Hospital, Chungcheongnam-do, Korea, Republic of
🇰🇷St. Mary's Eye center, Geyonggi-do, Korea, Republic of
Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®
- Conditions
- Dry Eye Syndromes
- Interventions
- First Posted Date
- 2015-09-21
- Last Posted Date
- 2017-06-01
- Lead Sponsor
- Allergan
- Target Recruit Count
- 51
- Registration Number
- NCT02554981
- Locations
- 🇺🇸
Andover Eye Associates, Inc, Andover, Massachusetts, United States
🇺🇸Total Eye Care, PA, Memphis, Tennessee, United States